SMLR Share Price Performance
US$18.47
-47.96 (-72.20%)
81.7% undervalued intrinsic discount
US$101.00
Fair Value
Price US$18.47
AnalystHighTarget US$101.00
AnalystLowTarget US$60.00
AnalystConsensusTarget US$65.67
Fair ValueUS$101.00
Share Pricen/a
Semler Scientific, Inc. Stock Price
- 3 Narratives written by author
- 0 Comments on narratives written by author
- 38 Fair Values set on narratives written by author
SMLR Community Narratives
AN
Fair Value US$101 81.7% undervalued intrinsic discount
Aging Population Will Drive Non-Invasive Diagnostic Adoption
0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
AN
Fair Value US$60 69.2% undervalued intrinsic discount
Bitcoin Volatility Will Erode Margins While SaaS Will Offer Hope
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
AN
Fair Value US$65.67 71.9% undervalued intrinsic discount
Cardiac And Digital Health Expansion Will Encounter Bitcoin Risks
0users have liked this narrative
0users have commented on this narrative
20users have followed this narrative
Cardiac And Digital Health Expansion Will Encounter Bitcoin Risks
Key Takeaways Diversification into cardiac disease markets and value-based care tools positions the company for higher recurring revenues and improved long-term margins. Unique strategy leveraging healthcare cash flow to invest in Bitcoin assets distinguishes its growth model and supports potential value appreciation.Read more
0users have liked this narrative
0users have commented on this narrative
20users have followed this narrative
AN
US$65.67
71.9% undervalued intrinsic discount
AnalystConsensusTarget Fair Value
Revenue growth
-29.67% p.a.
Profit Margin
91.46%
Future PE
128.82x
Share price in 2028
US$45.47
Bitcoin Volatility Will Erode Margins While SaaS Will Offer Hope
Key Takeaways Heavy dependence on a single device and slow product diversification exposes Semler to competitive and technological risks that may undermine future revenue. Regulatory pressures, limited international expansion, and intensifying competition threaten margin growth and the ability to capitalize on healthcare market trends.Read more
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
AN
US$60
69.2% undervalued intrinsic discount
AnalystLowTarget Fair Value
Revenue growth
-11.1% p.a.
Profit Margin
12.32%
Future PE
364.52x
Share price in 2028
US$41.71
Aging Population Will Drive Non-Invasive Diagnostic Adoption
Key Takeaways Rapid expansion into new diagnostic and digital asset markets could drive substantial revenue, asset growth, and earnings leverage beyond mainstream expectations. The shift to value-based care and remote diagnostics positions Semler to capture outsized market share and operational efficiency in chronic disease management.Read more
0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
AN
US$101
81.7% undervalued intrinsic discount
AnalystHighTarget Fair Value
Revenue growth
-23.4% p.a.
Profit Margin
36.91%
Future PE
427.39x
Share price in 2028
US$142.48
Recently Updated Narratives
AN
Cardiac And Digital Health Expansion Will Encounter Bitcoin Risks
Fair Value: US$65.67 71.9% undervalued intrinsic discount
20 followersusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
Bitcoin Volatility Will Erode Margins While SaaS Will Offer Hope
Fair Value: US$60 69.2% undervalued intrinsic discount
0 followersusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
Aging Population Will Drive Non-Invasive Diagnostic Adoption
Fair Value: US$101 81.7% undervalued intrinsic discount
1 followerusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
Snowflake Analysis
Semler Scientific, Inc. Key Details
Last Reported Earnings
Sep 30, 2025
Next Reporting Earnings
n/a
- 3.19
- 90.76%
- 130.80%
- 25.3%
About SMLR
- Founded
- 2007
- Employees
- 79
- CEO
- WebsiteView website
Semler Scientific, Inc. provides technology solutions to enhance the clinical effectiveness and efficiency of healthcare providers in the United States. The company’s products include QuantaFlo, a four-minute in-office blood flow test that enables healthcare providers to use blood flow measurements as part of their examinations of a patient’s vascular condition. The company’s products serve cardiologists, internists, nephrologists, endocrinologists, podiatrists, family practitioners, healthcare insurance plans, integrated delivery networks, independent physician groups, and companies contracting with the healthcare industry, such as risk assessment groups and retailers. It offers its products through sales representatives and distributors. The company was incorporated in 2007 and is headquartered in Santa Clara, California.
